tiprankstipranks
Trending News
More News >

Chimeric Therapeutics Reports Promising Results in CAR-T Cell Trial for GI Cancers

Story Highlights
Chimeric Therapeutics Reports Promising Results in CAR-T Cell Trial for GI Cancers

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).

Chimeric Therapeutics has announced promising translational data from its Phase 1/2 trial of CHM CDH17 CAR-T cells, which target cadherin 17, a protein overexpressed in gastrointestinal tumors. The trial showed that the CAR-T cells persisted in patients for up to six months after a single infusion, indicating potential efficacy in treating advanced gastrointestinal cancers. This development enhances Chimeric’s confidence in advancing the clinical dose finding process and could significantly impact its positioning in the oncology cell therapy market.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics is a clinical stage cell therapy company focused on developing innovative cell therapies for cancer treatment. The company has a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies, with assets being developed across multiple oncology areas. Chimeric’s team is dedicated to the discovery, development, and commercialization of promising cell therapies, with four clinical stage programs currently underway.

Technical Sentiment Signal: Sell

Current Market Cap: A$8.06M

Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1